Abstract
We investigated the incidence of non-embolic adverse events in 2 cohorts of AF patients and validated the 2MACE score [(metabolic syndrome, age ≥75) [ cohort, follow-up was performed through routine visits to the anticoagulation clinic and through medical records. Importantly, no patient was lost to follow-up.
In addition, we also included consecutive AF patients from the FANTASIIA (Spanish acronym for "Fibrilación Auricular: influencia del Nivel y Tipo de Anticoagulación Sobre la Comparisons of ROC curves between 2MACE score and CHA 2 DS 2 -VASc score were carried out by the DeLong et al. method. 4 Additionally, we used the methods described by Zhou et al. 5 for calculating the weighted summary area under the ROC curve under the fixed effects model and random effects model. Integrated discriminatory improvement (IDI) and net reclassification improvement (NRI) were performed according to the methods described by
Pencina et al. 6 Finally, clinical usefulness and net benefit of the 2MACE score in comparison with CHA 2 DS 2 -VASc were estimated using decision curve analysis (DCA). 7, 8 In all analyses, p values <0.05 were accepted as statistically significant. Statistical analyses were performed using SPSS v. 19 Figure 1) . The overall risk for each score point was 1.50 (95% CI 1.30-1.74, p<0.001) in our cohort, and 1.52 (95% CI 1.28-1.80, p<0.001) in the FANTASIIA registry.
ROC curve analysis demonstrated that the 2MACE score had a good performance for predict MACE in AF patients of our cohort, with a c-index of 0.662 (95% CI 0.625-0.697, p<0.001). This analysis showed the 2MACE score >2 as the best combination of sensitivity (64.6%) and specificity (60.0%). The cohort of the FANTASIIA registry showed similar results and the 2MACE score had a c-index of 0.656 (95% CI 0.593-0.719, p<0.001), with the score ≥3 presenting the best combination of sensitivity (61.7 %) and specificity (69.5%).
Comparisons of the ROC curves of 2MACE and CHA 2 DS 2 -VASc scores proved that the 2MACE score had better predictive ability for predict MACE, both, in our Murcia cohort (0.662 vs. 0.618, p=0.008) and in the FANTASIIA cohort (0.656 vs. 0.565, p=0.003) ( Table   3 , Supplementary Figure 2 (Figure 1 ).
Reclassification analyses showed significant improvement in sensitivity and important positive reclassification of the 2MACE score compared with the CHA 2 DS 2 -VASc score, based on the IDI and NRI (Table 3) .
Finally, decision curve analyses (DCA) graphically demonstrates that the overall risk of MACE in the MURCIA AF cohort was approximately 9%, according to the intersection of the y-axis and the slanted dash grey line. In the FANTASIIA population, the overall risk was around 30%. In both cohorts, as the lines of the 2MACE score are farthest away from the slanted dash grey lines (i.e., assume all MACE) and the horizontal black lines (i.e., assume none MACE), the 2MACE score demonstrates improved clinical usefulness and a higher net benefit compared to the CHA 2 DS 2 -VASc score (Figure 2 ).
Discussion
In this first study validating the 2MACE score in 'real world' patients taking both, VKA and NOACs, we show that this novel score has a moderate predictive performance for MACEs in two different cohorts of AF patients.
Patients with AF are under a high risk of ischemic stroke and mortality. [9] [10] [11] [12] Our study confirms that other adverse cardiovascular events are frequent in these patients, with an incidence close to 3%/year in a population taking VKAs or NOACs, a rate which is even higher than that for stroke. This has been highlighted in previous studies that show that AF is associated with a risk of myocardial infarction due to the coexistence of atherosclerotic risk factors and is associated with the presence of some biomarkers also present in patients with coronary heart disease. [13] [14] [15] [16] [17] [18] [19] Given this information, it seems useful to have a simple clinical risk score to easily classify those AF patients at increased risk of cardiovascular events. 20 As well as CHA 2 DS 2 -VASc and HAS-BLED are widely used in clinical practice to estimate, respectively, the risk of ischemic stroke and bleeding, the new 2MACE score has proved to be useful for predicting MACE, with implications for clinical practice by aiding decision-making about antithrombotic therapies.
We have also compared the predictive ability for MACE of CHA 2 DS 2 -VASc and 2MACE scores. In previous studies, the predictive performance for non-stroke events of the CHA 2 DS 2 -VASc score has been investigated, and has proved to be useful predicting nonembolic adverse cardiovascular events. [21] [22] [23] [24] [25] Although in this study the CHA 2 DS 2 -VASc score remained a modest c-index for MACE, the 2MACE score demonstrates significantly better predictive performance for these events. In addition, this novel score demonstrates better discrimination and reclassification ability, as well as higher net benefit and clinical usefulness in comparison with CHA 2 DS 2 -VASc.
In the present study, in our both cohorts of patients, the 2MACE score had a similar cindex as the external validation cohort of Pastori et al. (i.e., 0.66). Indeed, a score >2 in the Murcia AF cohort showed the best combination of sensitivity and specificity while in the original article by Pastori et al. the best combination was obtained by a score ≥3, 1 as was also confirmed in the FANTASIIA cohort. Importantly, we show that the 2MACE score can be useful in two different contexts. First, in AF patients taking VKA or NOAC from a multicenter registry in the short-term follow-up. Second, in AF patients well-controlled with VKA and during a long-term follow-up period. These observations potentially add value to this novel score for use in daily clinical practice.
This study has several limitations that should be noted. First, the Murcia AF cohort is a Caucasian based population from a single centre. Second, all patients were treated with VKA (INR 2.0-3.0) during the previous 6 months to ensure homogeneity at baseline. We acknowledge that this inclusion criterion may not reflect 'typical' clinical practice, but the long follow-up and the standard care received make this cohort suitable. The FANTASIIA observational registry includes patients taking VKA or NOAC and its design is multicenter.
However, individual incidence rates of MACE presents in this study may be low, since the follow-up is yet only of 1 year and the planned complete follow-up for three years is ongoing.
Although our datasets were collected prospectively, all statistical analyses were performed retrospectively. This led us to define the MetS according to the WHO criteria, since at the end of follow-up we did not have the waist circumference of all patients.
In conclusion, in 'real world' AF patients, the 2MACE score is a good predictor of MACE. A score ≥3 should be used to categorize patients at 'high risk', in identifying patients at risk of MACE. This analysis shows the clinical usefulness of each score based on a continuum of potential thresholds for major adverse cardiovascular events (x-axis) and the net benefit of using the model to stratify patients at risk (y-axis) relative to assuming that no patient will have a major adverse cardiovascular event. 
